Method for treating or preventing sclerotic disorders using CD-2 binding agents
AssigneeAstellas US LLC
InventorAkshay K. Vaishnaw
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating or preventing fibrotic disorders, e.g., sclerotic disorders, for example scleroderma, using CD2-binding agents, e.g., LFA-3/IgG fusion polypeptides or LFA-3-binding agents, are provided.
Claims49
A method of treating a subject having scleroderma comprising administering to the subject a CD2-binding agent comprising a CD2-binding fragment of LFA-3 fused to all or part of an immunoglobulin hinge and further fused to the CH2 and CH3 regions of a human IgG1 heavy chain constant domain, in an amount sufficient to do one or more of:
- (a) attenuate the severity of the disorder,
- (b) suppress the deleterious effects of the disorder, or
- (c) preserve function of a visceral organ in the subject, and optionally further comprising administering an additional agent, wherein the additional agent is not an inhibitor of an ICAM-1/LFA-1 interaction.
A method of treating scleroderma in a subject, comprising administering to the subject a CD2-binding agent comprising a CD2-binding fragment of LFA-3 fused to all or part of an immunoglobulin hinge and further fused to the CH2 and CH3 regions of a human IgG1 heavy chain constant domain in an amount effective to treat said disorder, and optionally comprising administering an additional agent, wherein the additional agent is not an inhibitor of an ICAM-1/LFA-1 interaction.
Dependencies are inferred from the claim text.